keyword
MENU ▼
Read by QxMD icon Read
search

primary hypercholesterolemia

keyword
https://www.readbyqxmd.com/read/28918614/modifiable-co-morbidities-trends-during-hospital-admissions-for-obesity-in-france-2009-2014
#1
Pierre Nanyan
Obesity is a growing public health problem in France, but modifiable co-morbidities in obese patients during their hospital admissions excluding bariatric surgery are lacking. Data were extracted from the French national hospital discharge database. Data on patient admissions, age, gender, and length of stay were extracted by selecting any stay coded primary as obesity. Obesity was defined as body mass index (BMI) between 30-39 kg/m², and morbid obesity as BMI≥40 kg/m². Only modifiable co-morbidities frequently diagnosed during the 6-year period with a rate≥3% were chosen...
July 2017: Acta Medica Iranica
https://www.readbyqxmd.com/read/28918428/modification-of-cardiovascular-pharmacotherapy-in-palliative-care-patients-with-cancer-narrative-review
#2
Tomasz Pasierski
Palliative care cancer patients are treated with many drugs especially at the end of life. Limiting of polypharmacy a decreases the risk of associated adverse effects, medical errors and harmful drug interactions The time lag to benefit of many medications used for cardiovascular diseases or risk factors like hypertension, hypercholesterolemia is frequently longer than palliative care cancer patient's life expectancy. It is ethically appropriate to modify, even to discontinue cardiovascular pharmacotherapy when there is no prospect of benefit...
September 13, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/28902717/new-approaches-to-address-dyslipidemia
#3
Klaus G Parhofer
PURPOSE OF REVIEW: Although lipid-lowering treatment with statins, ezetimibe, and PCSK9 inhibitors is a very successful strategy to prevent cardiovascular events, there is a need for further drug developments. Not all patients respond sufficiently to the available therapy (very high baseline values, intolerance). Furthermore, patients may be characterized by dyslipidemias not accessible to available drugs such as patients with homozygous familial hypercholesterolemia, chylomicronemia syndrome, or elevated lipoprotein(a)...
September 11, 2017: Current Opinion in Lipidology
https://www.readbyqxmd.com/read/28886926/2017-focused-update-of-the-2016%C3%A2-acc%C3%A2-expert-consensus-decision-pathway-on-the-role-of-non-statin-therapies-for-ldl-cholesterol-lowering-in%C3%A2-the-management-of-atherosclerotic-cardiovascular-disease-risk-a-report-of-the-american-college-of-cardiology-task-force
#4
Donald M Lloyd-Jones, Pamela B Morris, Christie M Ballantyne, Kim K Birtcher, David D Daly, Sondra M DePalma, Margo B Minissian, Carl E Orringer, Sidney C Smith
In 2016, the American College of Cardiology published the first expert consensus decision pathway (ECDP) on the role of non-statin therapies for low-density lipoprotein (LDL)-cholesterol lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk. Since the publication of that document, additional evidence and perspectives have emerged from randomized clinical trials and other sources, particularly considering the longer-term efficacy and safety of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in secondary prevention of ASCVD...
August 30, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28879791/incorporation-of-pcsk9-inhibitors-into-prevention-of-atherosclerotic-cardiovascular-disease
#5
Cezary Wójcik
Primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) has become recently more complex than ever, leaving the clinicians perplexed with outdated guidelines and emerging evidence about new LDL-C lowering therapies. 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines have focused on high intensity statin therapy for specific groups of patients, while abandoning long established LDL-C goals, a strategy which no longer seems valid. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors have emerged as the add-on therapy on top of statins and/or ezetimibe for the treatment of hypercholesterolemia and ASCVD prevention...
September 7, 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/28878225/the-pdk1-inhibitor-dichloroacetate-controls-cholesterol-homeostasis-through-the-erk5-mef2-pathway
#6
Abrar Ul Haq Khan, Nerea Allende-Vega, Delphine Gitenay, Sabine Gerbal-Chaloin, Claire Gondeau, Dang-Nghiem Vo, Sana Belkahla, Stefania Orecchioni, Giovanna Talarico, Francesco Bertolini, Milica Bozic, Jose M Valdivielso, Fabienne Bejjani, Isabelle Jariel, Isabel C Lopez-Mejia, Lluis Fajas, Charles-Henri Lecellier, Javier Hernandez, Martine Daujat, Martin Villalba
Controlling cholesterol levels is a major challenge in human health, since hypercholesterolemia can lead to serious cardiovascular disease. Drugs that target carbohydrate metabolism can also modify lipid metabolism and hence cholesterol plasma levels. In this sense, dichloroacetate (DCA), a pyruvate dehydrogenase kinase (PDK) inhibitor, augments usage of the glycolysis-produced pyruvate in the mitochondria increasing oxidative phosphorylation (OXPHOS). In several animal models, DCA decreases plasma cholesterol and triglycerides...
September 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28867681/effect-of-intensive-and-standard-pitavastatin-treatment-with-or-without-eicosapentaenoic-acid-on-progression-of-coronary-artery-calcification-over-12-months%C3%A3-prospective-multicenter-study
#7
Toru Miyoshi, Kunihisa Kohno, Hirohiko Asonuma, Satoru Sakuragi, Makoto Nakahama, Yusuke Kawai, Tadahisa Uesugi, Takefumi Oka, Mitsuru Munemasa, Natsuki Takahashi, Naoki Mukohara, Seiji Habara, Yasushi Koyama, Kazufumi Nakamura, Hiroshi Ito
BACKGROUND: The effect of lipid-lowering agents on progression of coronary artery calcification (CAC) remains unclear. We evaluated the effects of pitavastatin 2 mg/day (PIT2), pitavastatin 4 mg/day (PIT4), and PIT2 combined with eicosapentaenoic acid (PIT2+EPA) on CAC progression.Methods and Results:This prospective multicenter study in Japan included patients with an Agatston score of 1-999, hypercholesterolemia, and no evidence of cardiovascular disease. Patients were allocated into PIT2, PIT4, or PIT2+EPA groups...
September 1, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28862926/alirocumab-treatment-and-achievement-of-non-high-density-lipoprotein-cholesterol-and-apolipoprotein-b-goals-in-patients-with-hypercholesterolemia-pooled-results-from-10-phase-3-odyssey-trials
#8
Harold E Bays, Lawrence A Leiter, Helen M Colhoun, Desmond Thompson, Laurence Bessac, Robert Pordy, Peter P Toth
BACKGROUND: Non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein (apo) B are better predictors of atherosclerotic cardiovascular disease risk than low-density lipoprotein cholesterol alone. US and European lipid management guidelines support non-HDL-C and apoB as targets for lipid-lowering therapy. METHODS AND RESULTS: This analysis evaluated the efficacy of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, on non-HDL-C and apoB...
August 8, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28826564/familial-hypercholesterolemia-in-a-european-mediterranean-population-prevalence-and-clinical-data-from-2-5-million-primary-care-patients
#9
Alberto Zamora, Luís Masana, Marc Comas-Cufí, Àlex Vila, Núria Plana, Maria García-Gil, Lia Alves-Cabratosa, Jaume Marrugat, Irene Roman, Rafel Ramos
BACKGROUND: Familial hypercholesterolemia (FH), the most frequent hereditary cause of premature coronary heart disease (CHD), is underdiagnosed and insufficiently treated. OBJECTIVES: The objectives of the study were to estimate the prevalence of the FH phenotype (FH-P) and to describe its clinical characteristics in a Mediterranean population. METHODS: Data were obtained from the Catalan primary care system's clinical records database (Catalan acronym: SIDIAP)...
July 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28821686/effect-of-simvastatin-on-csf-alzheimer-disease-biomarkers-in-cognitively-normal-adults
#10
Ge Li, Cynthia L Mayer, Daniel Morelli, Steven P Millard, Wendy H Raskind, Eric C Petrie, Monique Cherrier, Anne M Fagan, Murray A Raskind, Elaine R Peskind
OBJECTIVE: To examine potential disease-modifying effects of statin drugs, we conducted a 12-month randomized, placebo-controlled clinical trial of simvastatin in cognitively normal adults using change in CSF Alzheimer disease biomarkers as primary outcome measure. METHODS: Participants were 45-64 years old and statin-naive with normal cognition and normal or mildly elevated cholesterol. Forty-six participants completed the 1-year study per protocol (25 in the simvastatin and 21 in the placebo group)...
August 18, 2017: Neurology
https://www.readbyqxmd.com/read/28814835/efficacy-and-tolerability-of-two-different-formulations-of-atorvastatin-in-korean-patients-with-hypercholesterolemia-a-multicenter-prospective-randomized-clinical-trial
#11
Ju-Hee Lee, Sang-Hyun Kim, Dong-Ju Choi, Seung-Jea Tahk, Jung-Han Yoon, Si Wan Choi, Taek-Jong Hong, Hyo-Soo Kim
PURPOSE: This study was designed to compare the efficacy and tolerability of the generic formulation (Atorva(®)) and the reference formulation (Lipitor(®)) of atorvastatin, both at a dosage of 20 mg once daily. METHODS: This study was a prospective open-label, randomized controlled study. Hypercholesterolemic patients who had not achieved low-density lipoprotein (LDL) cholesterol goals according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) guideline were randomized to generic formulation or reference formulation of atorvastatin...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28810550/2d-sti-combined-with-gated-99-tc-m-mibi-mpi-for-the-diagnosis-of-myocardial-ischemia-in-hypercholesterolemia-patients
#12
Yi Song, Rui-Fang Zhang, Yu Liu
This study aimed to investigate the reliability of ultrasound two-dimensional speckle tracking imaging (2D-STI) for the evaluation of myocardial ischemia in familial hypercholesterolemia (FH) patients. We recruited 28 patients clinically diagnosed with homozygous familial hypercholesterolemia (HoFH) and subjected them to 2D-STI, gated transthoracic Doppler echocardiography (TTDE), and (99)Tc(m)-methoxyisobutylisonitrile myocardial perfusion imaging ((99)Tc(m)-MIBI MPI). The sensitivity, specificity and diagnostic accordance rate of TTDE and 2D-STI for myocardial ischemia in HoFH patients were compared with the (99)Tc(m)-MIBI scores...
August 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28807459/rapidly-progressive-atherosclerosis-after-domino-liver-transplantation-from-a-teenage-donor-with-homozygous-familial-hypercholesterolemia
#13
Jessica R Golbus, Linda Farhat, Robert J Fontana, Melvyn Rubenfire
Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by impaired clearance of low-density lipoprotein cholesterol. Given limitations in pharmacologic therapy and the significant morbidity and mortality associated with this disease, liver transplantation may be offered to select homozygous FH patients in childhood in an effort to slow progression of atherosclerotic cardiovascular disease. In rare cases, domino liver transplantation can be performed, transplanting the livers of patients with various metabolic disorders into elderly recipients whose projected survival precludes prolonged waiting on the transplant list...
July 22, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28792952/everolimus-long-term-use-in-patients-with-tuberous-sclerosis-complex-four-year-update-of-the-exist-2-study
#14
John J Bissler, J Chris Kingswood, Elzbieta Radzikowska, Bernard A Zonnenberg, Elena Belousova, Michael D Frost, Matthias Sauter, Susanne Brakemeier, Petrus J de Vries, Noah Berkowitz, Maurizio Voi, Severine Peyrard, Klemens Budde
OBJECTIVES: We examined the long-term effects of everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. METHODS: Following favorable results from the double-blind core phase of EXIST-2 (NCT00790400), patients were allowed to receive open-label everolimus (extension phase). Patients initially randomly assigned to everolimus continued on the same dose; those who were receiving placebo crossed over to everolimus 10 mg/day...
2017: PloS One
https://www.readbyqxmd.com/read/28768921/efficacy-and-safety-of-the-cholesteryl-ester-transfer-protein-inhibitor-evacetrapib-in-combination-with-atorvastatin-in-japanese-patients-with-primary-hypercholesterolemia
#15
Tamio Teramoto, Arihiro Kiyosue, Takeshi Iimura, Yasushi Takita, Jeffrey S Riesmeyer, Masahiro Murakami
BACKGROUND: Inhibition of cholesteryl ester transfer protein by evacetrapib when added to atorvastatin may provide an additional treatment option for patients who do not reach their low-density lipoprotein cholesterol (LDL-C) goal.Methods and Results:This multicenter, randomized, 12-week, double-blind, parallel-group, placebo-controlled, outpatient, phase 3 study evaluated the efficacy of evacetrapib with atorvastatin in reducing LDL-C in 149 Japanese patients (evacetrapib/atorvastatin, n=53; ezetimibe/atorvastatin, n=50; placebo/atorvastatin, n=46) with primary hypercholesterolemia...
August 3, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28765036/world-heart-federation-cholesterol-roadmap
#16
Adrianna Murphy, Jose R Faria-Neto, Khalid Al-Rasadi, Dirk Blom, Alberico Catapano, Ada Cuevas, Francisco Lopez-Jimenez, Pablo Perel, Raul Santos, Allan Sniderman, Rody Sy, Gerald F Watts, Dong Zhao, Salim Yusuf, David Wood
BACKGROUND: The World Heart Federation has undertaken an initiative to develop a series of Roadmaps. OBJECTIVES: The aim of these is to promote development of national policies and health systems approaches and identify potential roadblocks on the road to effective prevention, detection and management of cardiovascular disease (CVD) in low-and middle-income countries (LMIC), and strategies for overcoming these. This Roadmap focuses on elevated blood cholesterol, a leading risk factor for myocardial infarction, stroke, and peripheral arterial disease...
July 29, 2017: Global Heart
https://www.readbyqxmd.com/read/28762942/-recommendations-of-the-european-society-of-cardiology-and-the-european-atherosclerosis-society-on-cardiovascular-disease-prevention-and-management-of-dyslipidemias-for-the-diagnosis-of-atherosclerosis-and-dyslipidemia-treatment-2016-basic-s-g
#17
M G Bubnova, V V Kukharchuk
This review summarizes the main provisions of the new, issued in 2016, recommendations of the European Society of Cardiology and Atherosclerosis Society in cooperation with the European Association on Cardiovascular Prevention and Rehabilitation on Cardiovascular disease prevention and Management of dyslipidemia. In these recommendations, the following trends can be traced distinctly: priority in primary prevention is given to non-drug methods of influence; targets of hypolipidemic therapy are identified not only for low density lipoprotein (LDL) cholesterol (CH), but also for non-high density lipoprotein (HDL) CH, especially in cases of concomitant hypertriglyceridemia...
March 2017: Kardiologiia
https://www.readbyqxmd.com/read/28752495/changing-clinical-phenotypes-of-hiv-associated-neurocognitive-disorders
#18
Ned Sacktor
HIV-associated neurocognitive disorder (HAND) remains a common cause of cognitive impairment and persists in 15-55% of HIV+ individuals in the combination antiretroviral therapy (CART) era. CART is now the primary treatment for HAND, but it is effective in only a subset of patients. In the pre-CART era, HIV-associated dementia was the most common form of HAND. However, in CART-treated patients, the prevalence of HIV-associated dementia has declined substantially, and milder stages of HAND, i.e., ANI and MND predominate...
July 27, 2017: Journal of Neurovirology
https://www.readbyqxmd.com/read/28744105/pattern-of-statin-use-changes-following-media-coverage-of-its-side-effects
#19
Margit Kriegbaum, Kasper Bering Liisberg, Helle Wallach-Kildemoes
BACKGROUND: The media plays a role in shaping opinions about medical decisions, for example, whether to initiate or stop treatment. An association between negative media attention and statin discontinuation has been demonstrated, but it may differ depending on the reason for prescription and whether the user is new (incident) or long term (prevalent). AIM: The aim of this study is to explore whether a Danish newspaper article featuring the side effects of statins affects statin discontinuation in incident versus prevalent users, with the reason for prescription also taken into account...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28712132/impact-of-lipoprotein-apheresis-with-dextran-sulfate-adsorption-on-the-expression-of-genes-involved-in-cardiovascular-health-in-the-blood-of-patients-with-homozygous-familial-hypercholesterolemia
#20
Jean-Philippe Drouin-Chartier, André J Tremblay, Jean Bergeron, Nathalie Laflamme, Benoît Lamarche, Patrick Couture
Lipoprotein apheresis (LA) with dextran sulfate adsorption (DSA) is a reliable method to decrease LDL-cholesterol (C) concentrations in patients with homozygous familial hypercholesterolemia (HoFH). The objective of the present study was to investigate the impact of LA with DSA on the mRNA expression of genes associated with cardiovascular health in the whole blood of HoFH patients. Blood samples were collected before and after LA treatment with DSA in 9 HoFH patients. Microarray analyses were performed to measure the whole blood expression of >30 000 annotated genes pre- and post-LA...
July 16, 2017: Journal of Clinical Apheresis
keyword
keyword
65021
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"